Clinical Trial Update: INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating inhaled flecainide for converting recent-onset symptomatic atrial fibrillation to sinus rhythm; results were posted May 14, 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Atrial Fibrillation

Drugs mentioned

• flecainide (flecainide)

Snippet

Sponsor: InCarda Therapeutics, Inc. | Conditions: Paroxysmal Atrial Fibrillation (PAF) | Phase 2 | Status: COMPLETED | Results posted: 2024-05-14